Evolving Role and Translation of Radiomics and Radiogenomics in Adult and Pediatric Neuro-Oncology

References

1. 1.↵
   1. Zhou M,
   2. Scott J,
   3. Chaudhury B, et al

   . Radiomics in brain tumor: image assessment, quantitative feature descriptors, and machine-learning approaches. AJNR Am J Neuroradiol 2018;39:208–16 doi:10.3174/ajnr.A5391 pmid:28982791

   Abstract/FREE Full Text
2. 2.↵
   1. Colen RR,
   2. Rolfo C,
   3. Ak M, et al

   . Radiomics analysis for predicting pembrolizumab response in patients with advanced rare cancers. J Immunother Cancer 2021;9:e001752 doi:10.1136/jitc-2020-001752 pmid:33849924

   Abstract/FREE Full Text
3. 3.↵
   1. Lambin P,
   2. Rios-Velazquez E,
   3. Leijenaar R, et al

   . Radiomics: extracting more information from medical images using advanced feature analysis. Eur J Cancer 2012;48:441–46 doi:10.1016/j.ejca.2011.11.036 pmid:22257792

   CrossRefPubMedWeb of Science
4. 4.↵
   1. Habib A,
   2. Jovanovich N,
   3. Hoppe M, et al

   . MRI-based radiomics and radiogenomics in the management of low-grade gliomas: evaluating the evidence for a paradigm shift. J Clin Med 2021;10:1411 doi:10.3390/jcm10071411

   CrossRef
5. 5.↵
   1. Iv M,
   2. Zhou M,
   3. Shpanskaya K, et al

   . MR imaging-based radiomic signatures of distinct molecular subgroups of medulloblastoma. AJNR Am J Neuroradiol 2019;40:154–61 doi:10.3174/ajnr.A5899 pmid:30523141

   Abstract/FREE Full Text
6. 6.↵
   1. Kickingereder P,
   2. Burth S,
   3. Wick A, et al

   . Radiomic profiling of glioblastoma: identifying an imaging predictor of patient survival with improved performance over established clinical and radiologic risk models. Radiology 2016;280:880–89 doi:10.1148/radiol.2016160845 pmid:27326665

   CrossRefPubMed
7. 7.↵
   1. Lin P,
   2. Peng YT,
   3. Gao RZ, et al

   . Radiomic profiles in diffuse glioma reveal distinct subtypes with prognostic value. J Cancer Res Clin Oncol 2020;146:1253–62 doi:10.1007/s00432-020-03153-6 pmid:32065261

   CrossRefPubMed
8. 8.↵
   1. Nakamoto T,
   2. Takahashi W,
   3. Haga A, et al

   . Prediction of malignant glioma grades using contrast-enhanced T1-weighted and T2-weighted magnetic resonance images based on a radiomic analysis. Sci Rep 2019;9:19411 doi:10.1038/s41598-019-55922-0 pmid:31857632

   CrossRefPubMed
9. 9.↵
   1. Li M,
   2. Wang H,
   3. Shang Z, et al

   . Ependymoma and pilocytic astrocytoma: Differentiation using radiomics approach based on machine learning. J Clin Neurosci 2020;78:175–80 doi:10.1016/j.jocn.2020.04.080 pmid:32336636

   CrossRefPubMed
10. 10.↵
    1. Rodriguez Gutierrez D,
    2. Awwad A,
    3. Meijer L, et al

    . Metrics and textural features of MRI diffusion to improve classification of pediatric posterior fossa tumors. AJNR Am J Neuroradiol 2014;35:1009–15 doi:10.3174/ajnr.A3784 pmid:24309122

    Abstract/FREE Full Text
11. 11.↵
    1. Visser M,
    2. Petr J,
    3. Muller DMJ, et al

    . Accurate MR image registration to anatomical reference space for diffuse glioma. Front Neurosci 2020;14:585 doi:10.3389/fnins.2020.00585 pmid:32581699

    CrossRefPubMed
12. 12.↵
    1. Akkus Z,
    2. Sedlar J,
    3. Coufalova L, et al

    . Semi-automated segmentation of pre-operative low grade gliomas in magnetic resonance imaging. Cancer Imaging 2015;15:12 doi:10.1186/s40644-015-0047-z pmid:26268363

    CrossRefPubMed
13. 13.↵
    1. Hayes K,
    2. Buist R,
    3. Vincent TJ, et al

    . Comparison of manual and semi-automated segmentation methods to evaluate hippocampus volume in APP and PS1 transgenic mice obtained via in vivo magnetic resonance imaging. J Neurosci Methods 2014;221:103–11 doi:10.1016/j.jneumeth.2013.09.014 pmid:24091139

    CrossRefPubMed
14. 14.↵
    1. Zhao Z,
    2. Yang G,
    3. Lin Y, et al

    . Automated glioma detection and segmentation using graphical models. PLoS One 2018;13:e0200745 doi:10.1371/journal.pone.0200745 pmid:30130371

    CrossRefPubMed
15. 15.↵
    1. Kalavathi P,
    2. Prasath VB

    . Methods on skull stripping of MRI head scan images: a review. J Digit Imaging 2016;29:365–79 doi:10.1007/s10278-015-9847-8 pmid:26628083

    CrossRefPubMed
16. 16.↵
    1. Nyúl LG,
    2. Udupa JK

    . On standardizing the MR image intensity scale. Magn Reson Med 1999;42:1072–81 doi:10.1002/(SICI)1522-2594(199912)42:6<1072::AID-MRM11>3.0.CO;2-M pmid:10571928

    CrossRefPubMed
17. 17.↵
    1. Buades A,
    2. Coll B,
    3. Morel JM

    . A review of image denoising algorithms, with a new one. Multiscale Model Simul 2005;4:490–530 doi:10.1137/040616024

    CrossRef
18. 18.↵
    1. Vovk U,
    2. Pernus F,
    3. Likar B

    . A review of methods for correction of intensity inhomogeneity in MRI. IEEE Trans Med Imaging 2007;26:405–21 doi:10.1109/TMI.2006.891486 pmid:17354645

    CrossRefPubMedWeb of Science
19. 19.↵
    1. Cattell R,
    2. Chen S,
    3. Huang C

    . Robustness of radiomic features in magnetic resonance imaging: review and a phantom study. Vis Comput Ind Biomed Art 2019;2:19 doi:10.1186/s42492-019-0025-6 pmid:32240418

    CrossRefPubMed
20. 20.↵
    1. Chaurasia K,
    2. Garg PA

    . Brief Review on Texture Analysis Methods. American Society of Science and Engineering; 2013
21. 21.↵
    1. Parekh V,
    2. Jacobs MA

    . Radiomics: a new application from established techniques. Expert Rev Precis Med Drug Dev 2016;1:207–26 doi:10.1080/23808993.2016.1164013 pmid:28042608

    CrossRefPubMed
22. 22.↵
    1. Deo RC

    . Machine learning in medicine. Circulation 2015;132:1920–30 doi:10.1161/CIRCULATIONAHA.115.001593 pmid:26572668

    Abstract/FREE Full Text
23. 23.↵
    1. Colen RR,
    2. Ologun GO,
    3. Zinn P, et al

    . Radiomic signatures to predict response to targeted therapy and immune checkpoint blockade in melanoma patients (pts) on neoadjuvant therapy. J Clin Oncol 2020;38:10067 doi:10.1200/JCO.2020.38.15_suppl.10067

    CrossRef
24. 24.↵
    1. Elshafeey N,
    2. Kotrotsou A,
    3. Hassan A, et al

    . Multicenter study demonstrates radiomic features derived from magnetic resonance perfusion images identify pseudoprogression in glioblastoma. Nat Commun 2019;10:3170 doi:10.1038/s41467-019-11007-0 pmid:31320621

    CrossRefPubMed
25. 25.↵
    1. Rathore S,
    2. Akbari H,
    3. Rozycki M, et al

    . Radiomic MRI signature reveals three distinct subtypes of glioblastoma with different clinical and molecular characteristics, offering prognostic value beyond IDH1. Sci Rep 2018;8:5087 doi:10.1038/s41598-018-22739-2 pmid:29572492

    CrossRefPubMed
26. 26.↵
    1. Sompong C,
    2. Wongthanavasu S

    . Brain tumor segmentation using cellular automata-based fuzzy c-means. In: Proceedings of the International Joint Conference on Computer Science and Software Engineering, Khon Kaen, Thailand. July 13-15;2016:1–6 doi:10.1109/JCSSE.2016.7748902

    CrossRef
27. 27.↵
    1. Kong DS,
    2. Kim J,
    3. Ryu G, et al

    . Quantitative radiomic profiling of glioblastoma represents transcriptomic expression. Oncotarget 2018;9:6336–45 doi:10.18632/oncotarget.23975 pmid:29464076

    CrossRefPubMed
28. 28.↵
    1. Parekh VS,
    2. Jacobs MA

    . Deep learning and radiomics in precision medicine. Expert Rev Precis Med Drug Dev 2019;4:59–72 doi:10.1080/23808993.2019.1585805 pmid:31080889

    CrossRefPubMed
29. 29.↵
    1. Parmar C,
    2. Grossmann P,
    3. Bussink J, et al

    . Machine learning methods for quantitative radiomic biomarkers. Sci Rep 2015;5:13087 doi:10.1038/srep13087 pmid:26278466

    CrossRefPubMed
30. 30.↵
    1. Sasaki T,
    2. Kinoshita M,
    3. Fujita K, et al

    . Radiomics and MGMT promoter methylation for prognostication of newly diagnosed glioblastoma. Sci Rep 2019;9:14435 doi:10.1038/s41598-019-50849-y pmid:31594994

    CrossRefPubMed
31. 31.↵
    1. Sun P,
    2. Wang D,
    3. Mok VC, et al

    . Comparison of feature selection methods and machine learning classifiers for radiomics analysis in glioma grading. IEEE Access 2019;7:102010–20 doi:10.1109/ACCESS.2019.2928975

    CrossRef
32. 32.↵
    1. Yang D,
    2. Rao G,
    3. Martinez J, et al

    . Evaluation of tumor-derived MRI-texture features for discrimination of molecular subtypes and prediction of 12-month survival status in glioblastoma. Med Phys 2015;42:6725–35 doi:10.1118/1.4934373 pmid:26520762

    CrossRefPubMed
33. 33.↵
    1. Prasanna P,
    2. Patel J,
    3. Partovi S, et al

    . Radiomic features from the peritumoral brain parenchyma on treatment-naive multi-parametric MR imaging predict long versus short-term survival in glioblastoma multiforme: preliminary findings. Eur Radiol 2017;27:4188–97 doi:10.1007/s00330-016-4637-3 pmid:27778090

    CrossRefPubMed
34. 34.↵
    1. Payabvash S,
    2. Aboian M,
    3. Tihan T, et al

    . Machine learning decision tree models for differentiation of posterior fossa tumors using diffusion histogram analysis and structural MRI findings. Front Oncol 2020;10:71 doi:10.3389/fonc.2020.00071 pmid:32117728

    CrossRefPubMed
35. 35.↵
    1. Kickingereder P,
    2. Gotz M,
    3. Muschelli J, et al

    . Large-scale radiomic profiling of recurrent glioblastoma identifies an imaging predictor for stratifying anti-angiogenic treatment response. Clin Cancer Res 2016;22:5765–71 doi:10.1158/1078-0432.CCR-16-0702 pmid:27803067

    Abstract/FREE Full Text
36. 36.↵
    1. Chen T,
    2. Guestrin C

    . XGBoost: a scalable tree boosting system. In: Proceedings of the 22nd ACM SIGKDD International Conference on Knowledge Discovery and Data Mining. Association for Computing Machinery; 2016:785–94
37. 37.↵
    1. Koçak B,
    2. Durmaz EŞ,
    3. Ateş E, et al

    . Radiomics with artificial intelligence: a practical guide for beginners. Diagn Interv Radiol 2019;25:485–95 doi:10.5152/dir.2019.19321 pmid:31650960

    CrossRefPubMed
38. 38.↵
    1. Kumar V,
    2. Gu Y,
    3. Basu S, et al

    . Radiomics: the process and the challenges. Magn Reson Imaging 2012;30:1234–48 doi:10.1016/j.mri.2012.06.010 pmid:22898692

    CrossRefPubMed
39. 39.↵
    1. Zinn PO,
    2. Majadan B,
    3. Sathyan P, et al

    . Radiogenomic mapping of edema/cellular invasion MRI-phenotypes in glioblastoma multiforme. PLoS One 2011;6:e25451 doi:10.1371/journal.pone.0025451 pmid:21998659

    CrossRefPubMed
40. 40.↵
    1. Cho HH,
    2. Lee SH,
    3. Kim J, et al

    . Classification of the glioma grading using radiomics analysis. PeerJ 2018;6:e5982 doi:10.7717/peerj.5982 pmid:30498643

    CrossRefPubMed
41. 41.↵
    1. Choi YS,
    2. Ahn SS,
    3. Chang JH, et al

    . Machine learning and radiomic phenotyping of lower grade gliomas: improving survival prediction. Eur Radiol 2020;30:3834–42 doi:10.1007/s00330-020-06737-5 pmid:32162004

    CrossRefPubMed
42. 42.↵
    1. Fan Y,
    2. Chen C,
    3. Zhao F, et al

    . Radiomics-based machine learning technology enables better differentiation between glioblastoma and anaplastic oligodendroglioma. Front Oncol 2019;9:1164 doi:10.3389/fonc.2019.01164 pmid:31750250

    CrossRefPubMed
43. 43.↵
    1. Han Y,
    2. Xie Z,
    3. Zang Y, et al

    . Non-invasive genotype prediction of chromosome 1p/19q co-deletion by development and validation of an MRI-based radiomics signature in lower-grade gliomas. J Neurooncol 2018;140:297–306 doi:10.1007/s11060-018-2953-y pmid:30097822

    CrossRefPubMed
44. 44.↵
    1. Lohmann P,
    2. Lerche C,
    3. Bauer EK, et al

    . Predicting IDH genotype in gliomas using FET PET radiomics. Sci Rep 2018;8:13328 doi:10.1038/s41598-018-31806-7 pmid:30190592

    CrossRefPubMed
45. 45.↵
    1. Su C,
    2. Jiang J,
    3. Zhang S, et al

    . Radiomics based on multicontrast MRI can precisely differentiate among glioma subtypes and predict tumour-proliferative behaviour. Eur Radiol 2019;29:1986 doi:10.1007/s00330-018-5704-8 pmid:30315419

    CrossRefPubMed
46. 46.↵
    1. Zhang B,
    2. Chang K,
    3. Ramkissoon S, et al

    . Multimodal MRI features predict isocitrate dehydrogenase genotype in high-grade gliomas. Neuro Oncol 2017;19:109–17 doi:10.1093/neuonc/now121 pmid:27353503

    CrossRefPubMed
47. 47.↵
    1. Zhou H,
    2. Chang K,
    3. Bai HX, et al

    . Machine learning reveals multimodal MRI patterns predictive of isocitrate dehydrogenase and 1p/19q status in diffuse low- and high-grade gliomas. J Neurooncol 2019;142:299–307 doi:10.1007/s11060-019-03096-0 pmid:30661193

    CrossRefPubMed
48. 48.↵
    1. Kickingereder P,
    2. Bonekamp D,
    3. Nowosielski M, et al

    . Radiogenomics of glioblastoma: machine learning-based classification of molecular characteristics by using multiparametric and multiregional MR imaging features. Radiology 2016;281:907–18 doi:10.1148/radiol.2016161382 pmid:27636026

    CrossRefPubMed
49. 49.↵
    1. Li J,
    2. Liu S,
    3. Qin Y, et al

    . High-order radiomics features based on T2 FLAIR MRI predict multiple glioma immunohistochemical features: a more precise and personalized gliomas management. PLoS One 2020;15:e0227703 doi:10.1371/journal.pone.0227703 pmid:31968004

    CrossRefPubMed
50. 50.↵
    1. Hu LS,
    2. Ning S,
    3. Eschbacher JM, et al

    . Radiogenomics to characterize regional genetic heterogeneity in glioblastoma. Neuro Oncol 2017;19:128–37 doi:10.1093/neuonc/now135 pmid:27502248

    CrossRefPubMed
51. 51.↵
    1. Colen RR,
    2. Hassan I,
    3. Elshafeey N, et al

    . Shedding light on the 2016 World Health Organization Classification of Tumors of the Central Nervous System in the era of radiomics and radiogenomics. Magn Reson Imaging Clin N Am 2016;24:741–49 doi:10.1016/j.mric.2016.07.001 pmid:27742114

    CrossRefPubMed
52. 52.↵
    1. Gutman DA,
    2. Cooper LA,
    3. Hwang SN, et al

    . MR imaging predictors of molecular profile and survival: multi-institutional study of the TCGA glioblastoma data set. Radiology 2013;267:560–69 doi:10.1148/radiol.13120118 pmid:23392431

    CrossRefPubMedWeb of Science
53. 53.↵
    1. Zinn PO,
    2. Singh SK,
    3. Kotrotsou A, et al

    . A co-clinical radiogenomic validation study: conserved magnetic resonance radiomic appearance of periostin expressing glioblastoma in patients and xenograft models. Clin Cancer Res 2018;24:6288–99 doi:10.1158/1078-0432.CCR-17-3420 pmid:30054278

    Abstract/FREE Full Text
54. 54.↵
    1. Reardon DA,
    2. Wen PY

    . Glioma in 2014: unravelling tumour heterogeneity: implications for therapy. Nat Rev Clin Oncol 2015;12:69–70 doi:10.1038/nrclinonc.2014.223 pmid:25560529

    CrossRefPubMed
55. 55.↵
    1. Lemee JM,
    2. Clavreul A,
    3. Menei P

    . Intratumoral heterogeneity in glioblastoma: don't forget the peritumoral brain zone. Neuro Oncol 2015;17:1322–32 doi:10.1093/neuonc/nov119 pmid:26203067

    CrossRefPubMed
56. 56.↵
    1. Li Y,
    2. Liu X,
    3. Qian Z, et al

    . Genotype prediction of ATRX mutation in lower-grade gliomas using an MRI radiomics signature. Eur Radiol 2018;28:2960–68 doi:10.1007/s00330-017-5267-0 pmid:29404769

    CrossRefPubMed
57. 57.↵
    1. Lin AL,
    2. White M,
    3. Miller-Thomas MM, et al

    . Molecular and histologic characteristics of pseudoprogression in diffuse gliomas. J Neurooncol 2016;130:529–33 doi:10.1007/s11060-016-2247-1 pmid:27704386

    CrossRefPubMed
58. 58.↵
    1. Xi YB,
    2. Guo F,
    3. Xu ZL, et al

    . Radiomics signature: a potential biomarker for the prediction of MGMT promoter methylation in glioblastoma. J Magn Reson Imaging 2018;47:1380–87 doi:10.1002/jmri.25860 pmid:28926163

    CrossRefPubMed
59. 59.↵
    1. Korfiatis P,
    2. Kline TL,
    3. Coufalova L, et al

    . MRI texture features as biomarkers to predict MGMT methylation status in glioblastomas. Med Phys 2016;43:2835–44 doi:10.1118/1.4948668 pmid:27277032

    CrossRefPubMed
60. 60.↵
    1. Akbari H,
    2. Bakas S,
    3. Pisapia JM, et al

    . In vivo evaluation of EGFRvIII mutation in primary glioblastoma patients via complex multiparametric MRI signature. Neuro Oncol 2018;20:1068–79 doi:10.1093/neuonc/noy033 pmid:29617843

    CrossRefPubMed
61. 61.↵
    1. Chang P,
    2. Grinband J,
    3. Weinberg BD, et al

    . Deep-learning convolutional neural networks accurately classify genetic mutations in gliomas. AJNR Am J Neuroradiol 2018;39:1201–07 doi:10.3174/ajnr.A5667 pmid:29748206

    Abstract/FREE Full Text
62. 62.↵
    1. Zinn PO,
    2. Singh SK,
    3. Kotrotsou A, et al

    . Distinct radiomic phenotypes define glioblastoma TP53-PTEN-EGFR mutational landscape. Neurosurgery 2017;64:203–10 doi:10.1093/neuros/nyx316 pmid:28899058

    CrossRefPubMed
63. 63.↵
    1. Kaloshi G,
    2. Benouaich-Amiel A,
    3. Diakite F, et al

    . Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome. Neurology 2007;68:1831–36 doi:10.1212/01.wnl.0000262034.26310.a2 pmid:17515545

    CrossRefPubMed
64. 64.↵
    1. Cha S

    . Neuroimaging in neuro-oncology. Neurotherapeutics 2009;6:465–77 doi:10.1016/j.nurt.2009.05.002 pmid:19560737

    CrossRefPubMedWeb of Science
65. 65.↵
    1. Al-Okaili RN,
    2. Krejza J,
    3. Woo JH, et al

    . Intraaxial brain masses: MR imaging-based diagnostic strategy–initial experience. Radiology 2007;243:539–50 doi:10.1148/radiol.2432060493 pmid:17456876

    CrossRefPubMedWeb of Science
66. 66.↵
    1. Chen C,
    2. Ou X,
    3. Wang J, et al

    . Radiomics-based machine learning in differentiation between glioblastoma and metastatic brain tumors. Front Oncol 2019;9:806 doi:10.3389/fonc.2019.00806 pmid:31508366

    CrossRefPubMed
67. 67.↵
    1. Kang D,
    2. Park JE,
    3. Kim YH, et al

    . Diffusion radiomics as a diagnostic model for atypical manifestation of primary central nervous system lymphoma: development and multicenter external validation. Neuro Oncol 2018;20:1251–61 doi:10.1093/neuonc/noy021 pmid:29438500

    CrossRefPubMed
68. 68.↵
    1. Kong Z,
    2. Jiang C,
    3. Zhu R, et al

    . (18)F-FDG-PET-based radiomics features to distinguish primary central nervous system lymphoma from glioblastoma. Neuroimage Clin 2019;23:101912 doi:10.1016/j.nicl.2019.101912 pmid:31491820

    CrossRefPubMed
69. 69.↵
    1. Ortiz-Ramon R,
    2. Larroza A,
    3. Ruiz-Espana S, et al

    . Classifying brain metastases by their primary site of origin using a radiomics approach based on texture analysis: a feasibility study. Eur Radiology 2018;28:4514–23 doi:10.1007/s00330-018-5463-6 pmid:29761357

    CrossRefPubMed
70. 70.↵
    1. Sun R,
    2. Limkin EJ,
    3. Vakalopoulou M, et al

    . A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study. Lancet Oncol 2018;19:1180–91 doi:10.1016/S1470-2045(18)30413-3 pmid:30120041

    CrossRefPubMed
71. 71.↵
    1. Tian Q,
    2. Yan LF,
    3. Zhang X, et al

    . Radiomics strategy for glioma grading using texture features from multiparametric MRI. J Magn Reson Imaging 2018;48:1518–28 doi:10.1002/jmri.26010 pmid:29573085

    CrossRefPubMed
72. 72.↵
    1. Theresia E,
    2. Malueka RG,
    3. Pranacipta S, et al

    . Association between Ki-67 labeling index and histopathological grading of glioma in Indonesian population. Asian Pac J Cancer Prev 2020;21:1063–68 doi:10.31557/APJCP.2020.21.4.1063 pmid:32334471

    CrossRefPubMed
73. 73.↵
    1. Grossmann P,
    2. Narayan V,
    3. Chang K, et al

    . Quantitative imaging biomarkers for risk stratification of patients with recurrent glioblastoma treated with bevacizumab. Neuro Oncol 2017;19:1688–97 doi:10.1093/neuonc/nox092 pmid:28499022

    CrossRefPubMed
74. 74.↵
    1. Szychot E,
    2. Youssef A,
    3. Ganeshan B, et al

    . Predicting outcome in childhood diffuse midline gliomas using magnetic resonance imaging based texture analysis. J Neuroradiol 2021;48:243–47 doi:10.1016/j.neurad.2020.02.005 pmid:32184119

    CrossRefPubMed
75. 75.↵
    1. McGarry SD,
    2. Hurrell SL,
    3. Kaczmarowski AL, et al

    . Magnetic resonance imaging-based radiomic profiles predict patient prognosis in newly diagnosed glioblastoma before therapy. Tomography 2016;2:223–28 doi:10.18383/j.tom.2016.00250 pmid:27774518

    CrossRefPubMed
76. 76.↵
    1. Narang S,
    2. Kim D,
    3. Aithala S, et al

    . Tumor image-derived texture features are associated with CD3 T-cell infiltration status in glioblastoma. Oncotarget 2017;8:101244–54 doi:10.18632/oncotarget.20643 pmid:29254160

    CrossRefPubMed
77. 77.↵
    1. Kotrotsou A,
    2. Zinn PO,
    3. Colen RR

    . Radiomics in brain tumors: an emerging technique for characterization of tumor environment. Magn Reson Imaging Clin N Am 2016;24:719–29 doi:10.1016/j.mric.2016.06.006 pmid:27742112

    CrossRefPubMed
78. 78.↵
    1. Arevalo OD,
    2. Soto C,
    3. Rabiei P, et al

    . Assessment of glioblastoma response in the era of bevacizumab: longstanding and emergent challenges in the imaging evaluation of pseudoresponse. Front Neurol 2019;10:460 doi:10.3389/fneur.2019.00460 pmid:31133966

    CrossRefPubMed
79. 79.↵
    1. Okada H,
    2. Weller M,
    3. Huang R, et al

    . Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. Lancet Oncol 2015;16:e534–42 doi:10.1016/S1470-2045(15)00088-1 pmid:26545842

    CrossRefPubMed
80. 80.↵
    1. Wan B,
    2. Wang S,
    3. Tu M, et al

    . The diagnostic performance of perfusion MRI for differentiating glioma recurrence from pseudoprogression: a meta-analysis. Medicine (Baltimore) 2017;96:e6333 doi:10.1097/MD.0000000000006333 pmid:28296759

    CrossRefPubMed
81. 81.↵
    1. Huang RY,
    2. Neagu MR,
    3. Reardon DA, et al

    . Pitfalls in the neuroimaging of glioblastoma in the era of antiangiogenic and immuno/targeted: detecting illusive disease, defining response. Front Neurol 2015;6:33 doi:10.3389/fneur.2015.00033 pmid:25755649

    CrossRefPubMed
82. 82.↵
    1. Paugh BS,
    2. Qu C,
    3. Jones C, et al

    . Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease. J Clin Oncol 2010;28:3061–68 doi:10.1200/JCO.2009.26.7252 pmid:20479398

    Abstract/FREE Full Text
83. 83.↵
    1. Siegel R,
    2. Naishadham D,
    3. Jemal A

    . Cancer statistics, 2013. CA Cancer J Clin 2013;63:11–30 doi:10.3322/caac.21166 pmid:23335087

    CrossRefPubMedWeb of Science
84. 84.↵
    1. Dong J,
    2. Li L,
    3. Liang S, et al

    . Differentiation between ependymoma and medulloblastoma in children with radiomics approach. Acad Radiol 2021;28:318–27 doi:10.1016/j.acra.2020.02.012 pmid:32222329

    CrossRefPubMed
85. 85.↵
    1. Fetit AE,
    2. Novak J,
    3. Rodriguez D, et al

    . Radiomics in paediatric neuro-oncology: a multicentre study on MRI texture analysis. NMR Biomed 2018 Jan 3 [Epub ahead of print] doi:10.1002/nbm.3781 pmid:29073725

    CrossRefPubMed
86. 86.↵
    1. Khatua S,
    2. Cooper LJN,
    3. Sandberg DI, et al

    . Phase I study of intraventricular infusions of autologous ex-vivo-expanded NK cells in children with recurrent medulloblastoma and ependymoma. Neuro Oncol 2020;22:1214–25 doi:10.1093/neuonc/noaa047 pmid:32152626

    CrossRefPubMed
87. 87.↵
    1. Zhou H,
    2. Hu R,
    3. Tang O, et al

    . Automatic machine learning to differentiate pediatric posterior fossa tumors on routine MR imaging. AJNR Am J Neuroradiol 2020;41:1279– 85 doi:10.3174/ajnr.A6621 pmid:32661052

    Abstract/FREE Full Text
88. 88.↵
    1. Fetit AE,
    2. Novak J,
    3. Rodriguez D, et al

    . 3D texture analysis of heterogeneous MRI data for diagnostic classification of childhood brain tumours. Stud Health Technol Inform 2015;213:19–22 pmid:26152942

    PubMed
89. 89.↵
    1. Northcott PA,
    2. Robinson GW,
    3. Kratz CP, et al

    . Medulloblastoma. Nat Rev Dis Primers 2019;5:11 doi:10.1038/s41572-019-0063-6 pmid:30765705

    CrossRefPubMed
90. 90.↵
    1. Kumar R,
    2. Liu APY,
    3. Orr BA, et al

    . Advances in the classification of pediatric brain tumors through DNA methylation profiling: from research tool to frontline diagnostic. Cancer 2018;124:4168–80 doi:10.1002/cncr.31583 pmid:30255939

    CrossRefPubMed
91. 91.↵
    1. Wagner MW,
    2. Hainc N,
    3. Khalvati F, et al

    . Radiomics of pediatric low-grade gliomas: toward a pretherapeutic differentiation of BRAF-mutated and BRAF-fused tumors. AJNR Am J Neuroradiol 2021;42:759–65 doi:10.3174/ajnr.A6998 pmid:33574103

    Abstract/FREE Full Text
92. 92.↵
    1. Foster JB,
    2. Madsen PJ,
    3. Hegde M, et al

    . Immunotherapy for pediatric brain tumors: past and present. Neuro Oncol 2019;21:1226–38 doi:10.1093/neuonc/noz077 pmid:31504801

    CrossRefPubMed
93. 93.↵
    1. Wang SS,
    2. Bandopadhayay P,
    3. Jenkins MR

    . Towards immunotherapy for pediatric brain tumors. Trends Immunol 2019;40:748–61 doi:10.1016/j.it.2019.05.009 pmid:31229353

    CrossRefPubMed
94. 94.↵
    1. Barredo Arrieta A,
    2. Díaz-Rodríguez N,
    3. Del Ser J, et al

    . Explainable Artificial Intelligence (XAI): concepts, taxonomies, opportunities and challenges toward responsible AI. Information Fusion 2020;58:82–115 doi:10.1016/j.inffus.2019.12.012

    CrossRef